Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Official title

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Study identification

NCT ID

NCT02488967

Recruitment status

Active, not recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

NRG Oncology

Other

Enrollment

782 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Jul 26, 2015 (Type not available)

Primary completion

Dec 31, 2025 (Actual)

Completion

Oct 31, 2026 (Estimated)

Last update posted

May 6, 2026

2015 – 2026

United States locations

U.S. sites

1286

U.S. states

49

U.S. cities

818